Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia; Post-traumatic stress disorders
- Focus Therapeutic Use
- 05 Jul 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 05 Jul 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 07 Jan 2021 Planned End Date changed from 30 Sep 2023 to 31 Dec 2024.